References
- 1. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz RD, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009 July 30;114(5):937-951. DOI: 10.1182/blood-2009-03-209262
- 2. Ley TJ, Mardis ER, Ding L, Fulton B, McLellan MD, Chen K, et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature. 2008 Nov 6;456(7218):66-72. DOI: 10.1038/nature07485
- 3. Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012 Jan 11;481(7382):506-10. DOI: 10.1038/nature10738
- 4. Damm F, Heuser M, Morgan M, Wagner K, Görlich K, Großhennig A, et al. Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. Blood. 2011 April 28;117(17):4561-4568. DOI: 10.1182/ blood-2010-08-303479
- 5. Patel JP, Gönen P, Figueroa ME, Fernandez H, Sun Z, Racevskis J, et al. Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia. N Engl J Med. 2012;366:1079-1089. DOI: 10.1056/NEJMoa1112304
- 6. Patel KP, Ravandi F, Ma D, Paladugu A, Barkoh BA, Medeiros LJ, et al. Acute Myeloid Leukemia With IDH1 or IDH2 Mutation Frequency and Clinicopathologic Features. Am J Clin Pathol. 2011 Jan;135(1):35-45. DOI: 10.1309/AJCPD7NR2RMNQDVF
- 7. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, et al. DNMT3A Mutations in Acute Myeloid Leukemia. N Engl J Med. 2010;363:2424-2433. DOI: 10.1056/NEJMoa1005143
- 8. Estey EH. Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol. 2012 Jan;87(1):89-99. DOI: 10.1002/ajh.22246
- 9. van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia. 1999 Dec;13(12):1901-28. DOI: 10.1038/sj.leu.2401592
- 10. Cairoli R, Beghini A, Grillo G, Nadali G, Elice F, Ripamonti CR, et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood 2006. 107(9):3463-8. DOI: 10.1182/blood-2005-09-3640
- 11. Care RS, Valk PM, Goodeve AC, Abu-Duhier FM, Geertsma-Kleinekoort W, Wilson GA, et al. Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol. 2003 Jun;121(5):775-7. DOI: 10.1046/j.1365-2141.2003.04362.x
- 12. Ladetto M, Bruggemann M, Ferrero S, Pepin F, Drandi D, Monitillo L, et al. Next-Generation Sequencing and Real-Time Quantitative PCR for Minimal Residual Disease (MRD) Detection Using the Immunoglobulin Heavy Chain Variable Region: A Methodical Comparison in Acute Lymphoblastic Leukemia (ALL), Mantle Cell Lymphoma (MCL) and Multiple Myeloma (MM). ASH 2012, abstract 788.
- 13. Schmitt MW, Kennedy S R, Salk JJ, Fox E J, Hiatt JB, Loeb LA. Detection of ultra-rare mutations by next-generation sequencing. Proc Natl Acad Sci USA. 2012 Sep 4;109(36):14508-13. DOI: 10.1073/pnas.1208715109
- 14. Gaidzik VI, Bullinger L, Schlenk RF, Zimmermann AS, Röck J, Paschka P, et al. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. J Clin Oncol. 2011 Apr 1;29(10):1364-72. DOI: 10.1200/ JCO.2010.30.7926
- 15. Wang F, Travins J, DeLaBarre B, Penard-Lacronique V, Schalm S, Hansen E, et al. Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation. Science. 2013 May 3;340(6132):622-6. DOI: 10.1126/science.1234769